PSC
GBT

Piper Sandler & Co’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Piper Sandler & Co’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-5,484
Closed -$288K – 29
2019
Q2 		$288K Buy
+5,484
New +$315K 0.38% 11
2016
Q1 		– Sell
-700
Closed -$23K – 29
2015
Q4 		$23K Buy
+700
New +$30.3K 0.06% 22

Other funds holding GBT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Piper Sandler & Co's GBT Position: Q3 2019 in Review

Piper Sandler & Co sold out of Global Blood Therapeutics, Inc. (GBT) in Q3 2019, closing a stake of 5,484 shares — an estimated $288K sold.

Piper Sandler & Co first reported a position in GBT in Q4 2015 and held it in 2 quarters. The position peaked at $288K in Q2 2019. 208 funds tracked by Wall St. Rank hold GBT as of Q3 2019.

  • Piper Sandler & Co reported no remaining Global Blood Therapeutics, Inc. position as of Q3 2019 after selling out during the quarter.
  • Piper Sandler & Co sold 5,484 Global Blood Therapeutics, Inc. shares in Q3 2019, an estimated $288K.
  • Piper Sandler & Co first reported a position in Global Blood Therapeutics, Inc. in Q4 2015 and held it in 2 quarters.
  • Piper Sandler & Co's Global Blood Therapeutics, Inc. position peaked at $288K in Q2 2019.
  • 208 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q3 2019.

Based on Piper Sandler & Co's 13F filing for Q3 2019, filed 14 Nov 2019.